Amylin is having a moment. It's the 'other' appetite hormone — the one that isn't GLP-1 — and suddenly everyone is talking about cagrilintide. Meanwhile there's already an amylin drug that got approved twenty years ago, and almost nobody mentions it. Let's fix that. No doses here, no protocols, just the honest picture.
What's the actual difference?
First, what amylin even is. When you eat, your pancreas doesn't only release insulin. It also releases a second hormone called amylin, which does three things: it slows how fast food leaves your stomach, it tells your brain you're full, and it dampens a sugar-raising signal called glucagon. Copy that hormone in a lab and you get an 'amylin analog' — which is what both of these peptides are.
Pramlintide is the one that crossed the finish line. It's sold as Symlin, it's FDA-approved, and it's used at mealtimes alongside insulin by people with type 1 or type 2 diabetes. Cagrilintide is the newer, longer-acting one that's still in clinical trials, usually studied paired with semaglutide under the name CagriSema. So the real difference isn't chemistry. It's that one has a regulator's signature and one doesn't — yet.
The head-to-head
| Factor | Pramlintide | Cagrilintide |
|---|---|---|
| What it is | A man-made copy of amylin, the mealtime fullness hormone | A newer, longer-acting amylin analog |
| Approved? | Yes — FDA-approved as Symlin, prescription-only | No — investigational, still in clinical trials |
| What it's studied for | Mealtime blood sugar control in type 1 and type 2 diabetes, alongside insulin | Weight loss, usually tested with semaglutide as 'CagriSema' |
| Strength of evidence | Strong — year-long randomized human trials supported approval | Growing — large Phase 3 human trials (REDEFINE) published, but not yet approved |
| Weight loss? | Yes, but modest — and it was never approved as a weight-loss drug | That's the whole point of the trials; results look substantial |
| Main catch | Boxed warning for severe low blood sugar when used with insulin | Not approved; 'research chemical' copies are not the trial drug |
| Banned in sport? | Not a WADA-listed peptide category like GH secretagogues | Not a WADA-listed peptide category like GH secretagogues |
Pramlintide: the approved one nobody talks about
Pramlintide has something cagrilintide doesn't: a finished regulatory story. Year-long randomized trials in both type 1 and type 2 diabetes showed it improved long-term blood sugar control and, as a bonus, weight, when added to insulin. Shorter human studies also found it reduced how much people ate and how big their meals were.
But here's the honest part people skip. The weight effect is modest, not transformative. It's injected before meals, not once a week. And it carries a boxed warning — the strongest warning the FDA uses — for severe low blood sugar, because combining it with insulin can push blood sugar down too far. It was approved as a diabetes drug used with insulin, full stop. It has never been approved as a weight-loss drug.
Cagrilintide: the hyped one
Cagrilintide is what the amylin hype is actually about. It's designed to last much longer than pramlintide, and it's mostly being tested combined with semaglutide as CagriSema. The Phase 3 REDEFINE trials — real, large, published human trials — reported meaningful weight loss, which is why the whole 'amylin is the next big thing' conversation exists.
None of that makes it available. It is not an approved medicine. And this matters more than it sounds: vials labelled 'cagrilintide' on research-chemical websites are not the drug used in those trials. They aren't made to pharmaceutical standards, nobody checks what's actually in them, and the trial results tell you nothing about what's in an unregulated vial.
Which one is better?
It depends on what 'better' means, and the honest answer splits two ways.
If better means 'proven and legally available' — pramlintide, easily. It's a real medicine you can get with a prescription, from a pharmacy, under a doctor, with a known safety profile. If better means 'more impressive weight-loss numbers' — the cagrilintide trial data looks stronger, but you cannot legally or safely act on that, because it isn't approved and the grey-market version isn't the same substance. A better drug you can't verify is worse than an okay drug you can.
What's actually true
- Both are amylin analogs — lab copies of a natural mealtime fullness hormone
- Pramlintide is FDA-approved (Symlin), prescription-only, for diabetes alongside insulin
- Cagrilintide is investigational, mostly trialled with semaglutide as CagriSema
- Pramlintide's weight effect is real but modest, and it was never approved for weight loss
What's just hype
- 'Cagrilintide is available now' — it's investigational, not approved
- 'Research-grade cagrilintide is the same thing as the trial drug' — it isn't, and nobody checks it
- 'Pramlintide is a weight-loss shot' — it's a diabetes medicine with a boxed warning
The honest verdict
This is a rare case where the boring answer wins. Pramlintide is the amylin peptide that actually exists as a medicine — modest, approved, prescription-only, with real warnings attached. Cagrilintide has the better story and possibly the better future, but 'in trials' is not 'available,' and the version on sale to consumers isn't the version in the trials. If you're interested in the amylin pathway, the honest move is to watch the approval process and talk to a doctor — not to buy a vial.
What this does not mean
- This doesn't mean pramlintide is a weight-loss drug — it's approved for blood sugar control in diabetes, alongside insulin, and its weight effect is modest.
- This doesn't mean cagrilintide is available or safe to self-source — it's investigational, and consumer 'research' versions aren't the drug used in trials.
- This doesn't mean strong trial results transfer to an unregulated vial — the evidence applies to a pharmaceutical-grade product, not a grey-market copy.
- This is general info, not medical advice — a doctor decides whether any amylin-based medicine fits you.